By: Researcher Taymur
Understanding CFS Physical Condition
New research suggests that in people with chronic fatigue syndrome, because a specific biomarker of inflammation is present for years.
So people with chronic fatigue syndrome frequently find it difficult to understand how they feel exhausted and painful.
Because most people suffering from the disorder have had their symptoms dismissed as being “all in their minds,” so much like a mental illness. Therefore that’s not necessarily true.
New research shows the first “strong” proof that chronic fatigue syndrome (CFS) clinically referred to as myalgic encephalomyelitis (ME) is a physical disorder that can be caused by an infection.
Therefore “We now have evidence confirming what millions of people already know about this disease, that ME / CFS is not psychological,” said Dr. Mady Hornig, Director of Translational Research at the Center for Infection and Immunity and Associate Professor of Epidemiology at the Mailman School in Columbia in a press release.
Because Columbia researchers published a study that described changes in an individual’s immune system that contribute to the condition.
“This study provides what has eluded us for so long: unequivocal proof of ME / CFS immunological failure and clinical biomarkers of illness,” said Dr. W. Ian Lipkin, Director of the Center for Infection and Immunity and Professor of Neurology and Pathology at the Mailman School in Columbia.
The Columbia team says their work supports the hypothesis that after a serious infection, such as infectious mononucleosis, CFS may be caused in a “hit-and-run” fashion.
The cross-sectional study, published in the Science Advances journal, included examining 298 CFS patients and 348 individuals without the condition blood plasma samples.
Because in those with the disease, the researchers found different bio-markers produced by the immune system. So in those who have had the disease for less than three years and those who have had it for more than three years, they also found differences.
Those who had the disease for a shorter period of time had higher amounts of different cytokine types, or molecules that regulate the defensive response of your body to inflammation and infection.
In general, the Columbia team reports early-stage CFS patients have elevated interleukin-17A levels, a recognized biomarker of a compromised immune system.
However the researchers added that the elevated levels of biomarkers seem to subside after three years because after an infection, the immune system became drained after failing to calm down. So they compared it for an extended period of time to an engine running at high gear.
So “Our findings will speed up the diagnosis process after first fall ill individuals as well as discover new therapeutic approaches based on these early blood markers,” said Hornig, the study’s lead author.
Historically, the proper diagnosis of CFS has been concerning. The Institute of Medicine (IOM) states that no diagnosis has yet been made for up to 91 percent of the 2,5 million individuals who have chronic fatigue.
So a panel of experts at the IOM recommended earlier this month that chronic fatigue be identified as a systemic aversion exertion disease (SEID) and diagnostic criteria that better reflect scientific research be developed.
Because a prominent culprit in Interleukin-17A Autoimmune Disorders affects not only people with CFS.
Numerous chronic inflammatory conditions such as multiple sclerosis, psoriasis, and rheumatoid arthritis are associated with high levels of this specific cytokine Trusted Source.
However interleukin-17A is a potential target for Trusted Source biological therapies intended to dampen the immune system of the body in order to alleviate symptoms of these conditions.
Therefore in the United States January Cosentyx (secukinumab), a psoriasis drug that targets interleukin-17A to relax the body’s immune response, was approved by the Food and Drug administration.
Because an infection may also trigger psoriasis, an autoimmune disorder. So CFS is a common complaint in people with psoriatic arthritis, an inflammatory joint disease that may cause late-stage psoriasis in people.
However before researchers would test existing or experimental drugs on patients with CFS to target interleukin-17A, they say they need to replicate their results in a study that follows patients to observe how their levels of cytokine differ over time.
So there must be a better understanding of CFS before effective CFS treatments can occur so that it can be diagnosed earlier.
Therefore “Early diagnosis can provide different care options that are likely to vary from those that would be available in later stages of the disease,” Hornig said.